[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473251":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":69,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cisgender and transgender women",null,"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR\u002FRPF=FF. Captopril 25 mg is given orally.\n\nBlood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing.",[13,14],"Drug: Captopril Tablets","Drug: Iohexol",{"label":16,"type":10,"description":11,"interventionNames":17},"Cisgender and transgender men",[13,14],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Captopril Tablets","Captorpril challenge to each participant",[16,9],[25],"Capoten",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Iohexol","Iohexol infusion to evaluate measured GFR",[16,9],[31],"Omnipaque",[33],{"name":34,"affiliation":35,"role":36},"Sofia Ahmed, MD","Alberta Health services","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Darlene Y Sola, BScN","CONTACT","4032107434","dsola@ucalgary.ca",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"Victoria Riehl-Tonn, BN","4032109434","victoria.riehltonn@ucalgary.ca",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Calgary","Alberta","T2N 4Z6","Canada","CA",{"type":56,"coordinates":57},"Point",[58,59],-114.08529,51.05011,{"lat":59,"lon":58},[62,64,65,66],{"name":39,"role":40,"phone":63,"phoneExt":10,"email":42},"4036149431",{"name":44,"role":40,"phone":63,"phoneExt":10,"email":46},{"name":34,"role":36,"phone":10,"phoneExt":10,"email":10},{"name":67,"role":68,"phone":10,"phoneExt":10,"email":10},"Sandra Dumanski, MD","SUB_INVESTIGATOR",{"type":36,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sofia Ahmed","Principal Investigator","100473251","hormone-therapy-and-angiotensin-dependent-arterial-and-renal-vasoconstriction-in-humans-100473251",false,"NCT05442463","Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans","Hormone Therapy and Angiotensin-Dependent Arterial and Renal","Inclusion Criteria:\n\n* Age 18 to 90 years\n* Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)\n\nExclusion Criteria:\n\n* Cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)\n* Cerebrovascular disease (transient ischemic attacks or stroke)\n* History of hypertension (BP\\>140\u002F90 or use of antihypertensive medications)\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73m2\n* Diabetes mellitus (defined by history, use of hypoglycaemic agents or a fasting glucose \\>7mmol\u002FL)\n* Current smoker\n* Previous history of preeclampsia\n* Anabolic steroids, cortical steroids, or non-steroidal anti-inflammatory medications, or at the discretion of the investigator.",true,"ALL","18 Years","90 Years",{"count":84,"type":85},200,"ESTIMATED","OBSERVATIONAL","1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.\n2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.",[89],"Hormone Therapy",[91,92,93,94,95,96,97,98],"post menopausal hormone replacement therapy","transgender men","transgender women","nonbinary","cis gender","post menopause","HRT","hormone replacement therapy","2025-03-24",{"date":101,"type":102},"2025-03-27","ACTUAL",{"date":104,"type":102},"2020-11-30",{"date":106,"type":85},"2025-11-30",{"name":5,"class":6},1]